TPST

Tempest Therapeutics Inc

0.3742

Nov 10 • 3:59 PM ET +0.0128 (3.54%)

0.3700

Aftermarket • 7:30 PM ET -0.0042 (-1.12%)

Healthcare Biotechnology USA Nano NASD

Peers: TVRD ACTU CRDF IMRX BDTX HOWL KZIA OSTX ZNTL PRLD

| Held by: VXF VTI

Scroll to Statements

Index	-
Market Cap	7.48M
Enterprise Value	14.26M
Income	-40.47M
Sales	0.00M
Book/sh	-0.07
Cash/sh	0.04
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	4
IPO	Nov 12, 2012

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	9.59
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.38
Current Ratio	0.38
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-4.48
EPS next Y	-0.90
EPS next Q	-0.32
EPS this Y	54.98%
EPS next Y	68.42%
EPS next 5Y	-
EPS past 3/5Y	46.00% 76.03%
Sales past 3/5Y	- -
EPS Y/Y TTM	69.34%
Sales Y/Y TTM	-
EPS Q/Q	83.35%
Sales Q/Q	-
Earnings	Aug 13 AMC
EPS/Sales Surpr.	- -

Insider Own	39.64%
Insider Trans	3.01%
Inst Own	5.26%
Inst Trans	14.17%
ROA	-237.25%
ROE	-931.14%
ROIC	-780.86%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-26.03%
SMA50	-48.41%
SMA200	-73.67%
Trades

Shs Outstand	15.98M
Shs Float	12.07M
Short Float	2.00%
Short Ratio	0.09
Short Interest	0.24M
52W High	10.33 -96.38%
52W Low	0.36 3.94%
Volatility	15.86% 9.93%
ATR (14)	0.06
RSI (14)	24.24
Beta	-1.52
Rel Volume	0.12
Avg Volume	2.55M
Volume	295,324

Perf Week	-20.15%
Perf Month	-49.62%
Perf Quarter	-69.07%
Perf Half Y	-80.51%
Perf YTD	-86.96%
Perf Year	-96.18%
Perf 3Y	-99.11%
Perf 5Y	-99.75%
Perf 10Y	-100.00%
Recom	1.00
Target Price	7.00
Prev Close	0.36
Price	0.37
Change %	3.54%

Consensus

Strong Buy

Avg. Price Target

$7.00

Implied Upside

+1,770.7%

Analysts3incl. previous ratings

Rating Distribution2 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jan 22, 2026	Upgrade	HH.C. Wainwright	Neutral → Buy	$11	+2,839.6%
Apr 10, 2025	Downgrade	BScotiabank	Sector Outperform → Sector Perform
Apr 10, 2025	Downgrade	HH.C. Wainwright	Buy → Neutral
Mar 14, 2024	Initiated	BScotiabank	Sector Outperform	$13	+3,374.1%
Feb 08, 2024	Initiated	JJefferies	Buy	$15	+3,908.6%

Oct-14-26 08:00AM	Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise (GlobeNewswire) -6.77%
Sep-23-26 08:00AM	Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors (GlobeNewswire) -7.80%
Sep-15-26 04:05PM	Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform (GlobeNewswire) +60.18%
Sep-11-26 08:00AM	Tempest Therapeutics Announces Up to $7.5 Million Private Placement (GlobeNewswire)
Sep-08-26 08:30AM	Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
04:25PM	Loading…
Aug-13-26 04:25PM	Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) -13.25%
Jul-21-26 07:00AM	Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T (GlobeNewswire)
Jul-15-26 07:00AM	Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026 (GlobeNewswire) +9.13%
Jun-04-26 04:37PM	Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors (GlobeNewswire)
May-29-26 08:00AM	Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds (GlobeNewswire) -11.56%
May-14-26 04:15PM	Tempest Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) +13.59% -12.44%
May-06-26 07:00AM	Tempest Presents Clinical Update at ISCT 2026 Annual Meeting (GlobeNewswire) -6.05%
Apr-29-26 08:00AM	Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting (GlobeNewswire)
Apr-22-26 08:00AM	Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T (GlobeNewswire)
Apr-14-26 08:00AM	Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts (GlobeNewswire) +5.14%
09:00AM	Loading…
Mar-30-26 09:00AM	Tempest Reports Year End 2025 Financial Results and Provides Business Update (GlobeNewswire) -12.14%
Mar-23-26 08:00AM	Tempest Therapeutics Announces Up To $6 Million Private Placement (GlobeNewswire) -19.65%
Mar-11-26 08:00AM	Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026 (GlobeNewswire)
Feb-25-26 07:59AM	Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026 (GlobeNewswire) -6.43%
Feb-11-26 06:59AM	Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets (GlobeNewswire)
Feb-04-26 04:47PM	Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets (GlobeNewswire) -6.30%
Jan-20-26 05:20PM	Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders (GlobeNewswire) -5.15%
Nov-26-25 04:05PM	Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Nov-25-25 08:00AM	Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -23.26%
Nov-19-25 09:00AM	Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027 (GlobeNewswire) -48.59%
Nov-05-25 08:30AM	Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +9.10%
Aug-13-25 08:00AM	Vividion Therapeutics Appoints Sam Whiting, M.D., Ph.D., as Chief Medical Officer (Business Wire) +6.02%
Aug-11-25 04:12PM	Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +8.83% +9.99%
Jun-30-25 08:00AM	Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China (GlobeNewswire)
Jun-12-25 09:00AM	After Major Oncology Conference, All Eyes Turn to Industry Innovation (PR Newswire)
08:00AM	Loading…
Jun-11-25 08:00AM	Tempest Announces $4.6 Million Registered Direct Offering of Common Stock (GlobeNewswire) -15.88%
Jun-06-25 11:35AM	TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy (Zacks)
Jun-05-25 08:00AM	Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC (GlobeNewswire) +15.16%
May-13-25 04:28PM	Tempest Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Apr-28-25 04:05PM	Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting (GlobeNewswire) -6.26%
Apr-21-25 08:00AM	Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP (GlobeNewswire)
Apr-10-25 11:05AM	TPST to Evaluate Strategic Options for Pipeline Studies, Stock Up (Zacks) -18.04%
Apr-09-25 04:30PM	Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value (GlobeNewswire) +9.87%
Mar-27-25 04:10PM	Tempest Reports Year End 2024 Financial Results and Provides Business Update (GlobeNewswire) -8.08%
Mar-25-25 04:30PM	Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-13-25 08:00AM	FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP) (GlobeNewswire)
Feb-10-25 08:00AM	Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (GlobeNewswire)
Feb-07-25 04:30PM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-06-25 08:00AM	Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC) (GlobeNewswire)
Dec-06-24 04:30PM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-05-24 09:00PM	A Reverse Aging Gurus Trail of Failed Businesses (The Wall Street Journal)
Nov-25-24 04:30PM	Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-12-24 04:21PM	Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -10.50%
08:00AM	Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma (GlobeNewswire)
Oct-10-24 07:01AM	Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial (GlobeNewswire) -18.52%
07:00AM	Tempest Extends Limited Duration Stockholder Rights Plan (GlobeNewswire)
Sep-20-24 04:30PM	Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-18-24 08:00AM	Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs (GlobeNewswire) -6.62%
Sep-05-24 08:00AM	Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) +5.04%
Aug-23-24 04:30PM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-21-24 08:00AM	Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance (GlobeNewswire)
Aug-15-24 08:00AM	Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma (GlobeNewswire) +30.25%
Aug-08-24 04:56PM	Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -14.18%
Jun-20-24 08:13AM	Why Is Tempest Therapeutics (TPST) Stock Up 45% Today? (InvestorPlace) -29.47%
08:00AM	Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm (GlobeNewswire)
07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
Jun-18-24 06:22PM	Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma (GlobeNewswire)
Jun-07-24 04:30AM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-21-24 08:00AM	Tempest to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-09-24 04:29PM	Tempest Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -6.34%
Apr-26-24 04:05PM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-09-24 08:00AM	Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting (GlobeNewswire)
Apr-04-24 08:00AM	Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications (GlobeNewswire) -12.20%
Mar-19-24 09:53PM	TPST Stock Earnings: Tempest Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
04:25PM	Tempest Reports Year End 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-12-24 08:00AM	Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types (GlobeNewswire)
Mar-05-24 04:30PM	Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting (GlobeNewswire) +16.09%
Feb-26-24 08:00AM	Tempest to Present at the 44th Annual TD Cowen Healthcare Conference (GlobeNewswire)
Feb-02-24 04:30PM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-05-24 04:05PM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.60%
Dec-01-23 04:15PM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-20-23 08:00AM	Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire) +9.25%
Nov-08-23 05:17PM	Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -8.74% +16.31%
Oct-12-23 08:25AM	Why Is Tempest Therapeutics (TPST) Stock Down 35% Today? (InvestorPlace) -59.26%
Oct-11-23 04:29PM	TPST Stock: 7 Things to Know About Tempest Therapeutics (InvestorPlace) +3,972.53%
08:01AM	Tempest Adopts Limited Duration Stockholder Rights Plan (GlobeNewswire)
08:00AM	Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study (GlobeNewswire)
07:41AM	Why Is Tempest Therapeutics (TPST) Stock Up 325% Today? (InvestorPlace)
Oct-10-23 04:05PM	Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma (GlobeNewswire)
Sep-19-23 08:00AM	Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development (GlobeNewswire)
Sep-05-23 08:00AM	Tempest to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-10-23 04:13PM	Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +5.50%
Jul-19-23 08:00AM	Tempest Announces Publication in Cancer Research Communications Highlighting TPST-1495 Significantly Increased Potency Against Prostaglandin-Driven Tumor Models by Blocking EP2 and EP4 Together (GlobeNewswire)
May-31-23 04:05PM	Tempest to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) -5.85% -5.88%
May-25-23 05:00PM	Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers (GlobeNewswire) -9.76%
May-19-23 04:05PM	Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-10-23 04:15PM	Tempest Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Apr-28-23 08:00AM	Tempest Announces Positive Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma (GlobeNewswire) +23.26%
Apr-27-23 04:58PM	Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma (GlobeNewswire)
Apr-26-23 06:41PM	Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting (GlobeNewswire) -6.74%
Apr-17-23 09:00AM	Tempest Announces New Translational and Preclinical Data Presented at the 2023 AACR Annual Meeting (GlobeNewswire) +25.42%
Mar-22-23 05:26PM	Tempest Reports Year End 2022 Financial Results and Provides Business Update (GlobeNewswire) +6.52%
Mar-15-23 04:05PM	Tempest to Present Biomarker Data for TPST-1120 at the Society for Immunotherapy of Cancer (SITC) 2023 Spring Scientific Meeting (GlobeNewswire)
Mar-14-23 04:30PM	Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting (GlobeNewswire) +15.79%
Nov-22-22 04:05PM	Tempest to Present at the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Angel Matthew	CEO and President	Mar 24 '26	Buy	2.16	231,482	500,001	231,482	Jun 23 04:56 PM
Angel Matthew	CEO and President	Mar 24 '26	Buy	2.16	231,482	500,001	231,482	Mar 25 05:32 PM

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company's novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest Therapeutics was founded in 2011 and is headquartered in Brisbane, CA.

PresidentDr. Matthew Angel Ph.D.

CFOMs. Stephanie Horn-Warnock

Head of Business DevelopmentDr. Andrew Fang Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TPST

Tempest Therapeutics Inc

Upgrade your Finviz experience